Compare PFO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFO | ENTX |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | PFO | ENTX |
|---|---|---|
| Price | $9.56 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 31.8K | ★ 260.7K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $6.90 | $1.45 |
| 52 Week High | $8.51 | $3.22 |
| Indicator | PFO | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 42.69 |
| Support Level | $9.43 | $1.45 |
| Resistance Level | $9.51 | $1.78 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 95.24 | 37.29 |
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.